A new drug developed by Australian researchers has shown promising results in reducing sepsis in a Phase II clinical trial involving 180 patients. The carbohydrate-based treatment works by calming a dangerous immune reaction that can cause organ failure. With no specific anti-sepsis therapy currently available, the findings mark a major step forward. Researchers now aim to move into Phase III trials.
Quelle: ScienceDaily | Immunsystem
Titelbild/Grafik: ScienceDaily News
Möchten Sie zu diesem Inhalt ein Kommentar abgeben oder haben Sie dazu eine Frage, dann machen Sie dies bitte immer auf der Herausgeberseite!
Weiteres von ScienceDaily | Allergy
- First-ever 3D view shows how killer T cells destroy cancer
- Harvard scientists link gut bacteria to depression through hidden inflammation trigger
- A common nutrient could supercharge cancer treatment
- Scientists discover spice synergy that boosts anti-inflammation 100x
- This 5-day diet helped Crohn’s patients feel better fast
- This popular supplement may increase risk of birth defects, study finds
- Your daily coffee may be protecting your brain, 43-year study finds
- DNA origami vaccines could be the next leap beyond mRNA
- Scientists discover the switch that revives exhausted cancer-fighting T cells
- A bold new plan could finally cure type 1 diabetes
